ALLERGY THERAPEUTICS PLC – Appointment Of Executive Chairman
RNS Number : 0609O Allergy Therapeutics PLC 28 July 2026 Allergy Therapeutics plc (“Allergy Therapeutics” or the “Company” or
RNS Number : 0609O Allergy Therapeutics PLC 28 July 2026 Allergy Therapeutics plc (“Allergy Therapeutics” or the “Company” or
Strong 2020 performance despite COVID-19 challenge
24 June 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2020.
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announces its unaudited interim results for the six months ended 31 December 2019.
11 July 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2019 ahead of its Preliminary Results to be announced on 25 September 2019.
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that Mary Tavener will join the Board of Allergy Therapeutics as a Non-Executive Director with immediate effect.
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive Phase I safety and tolerability results of subcutaneous Acarovac MPL (Monophosphoryl Lipid A) in patients with house dust mite (HDM)-induced allergic rhinoconjunctivitis.
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces, through its adjuvant research division Bencard Adjuvant Systems, the publication of new research into the Group’s adjuvant system Microcrystalline Tyrosine (MCT®) combined with Virus-Like particles (VLPs).
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the outcome of successful discussions with the Paul Ehrlich Institut (PEI) in Germany and the Food and Drug Administration (FDA) in the US regarding the pivotal Phase III PQ Grass trial design. The trial, being planned for the US and Europe, will evaluate the efficacy and safety of the Group’s short course, aluminium-free pre-seasonal immunotherapy in the prevention of the symptoms of allergic rhinoconjunctivitis caused by grass pollen.
Interim Results for the six months ended 31 December 2018. Continued good sales growth and strong operating profit with pipeline progressing well with PQ Birch results due Q1 and house dust mite results due in H1.